Cytena Owners Agree to Sell All Shares to Cellink
A strategic agreement has been announced that will see all shares of Cytena be sold to Cellink for a purchase price of EUR30.25 million (US$33.79 million).
A strategic agreement has been announced that will see all shares of Cytena, a life-sciences company focused on single-cell technologies, be sold to Cellink, a 3D bioprinter specialist, for a purchase price of EUR30.25 million (US$33.79 million).
The reasoning for the strategic acquisition has been specified as being synergy between the companies, which is anticipated to enable market opportunities, and a desire by Cellink to expand into the pharmaceutical space.
“In Cellink, we have found a great partner, which shares our vision for the company and will help us to further accelerate Cytena’s growth,” said Jonas Schoendube, CEO, Cytena in an Aug. 5, 2019 press release. “We see interesting synergies in marketing, sales, and R&D between all four group member companies […] Our customers and partners will benefit from an extended product offering and a stronger global presence.”
“We are excited to welcome Cytena to the Cellink family of life-science companies with this strategic acquisition,” added Erik Gatenholm, CEO, Cellink. “We are furthering CELLINK's global commercial strategy by focusing on the pharmaceutical industry […] With Cytena’s technology platforms, we will streamline workflows for our present and future customers, and enhance our presence in the pharmaceutical industry, a strategy that is well aligned with our vision. Together with Dispendix, we will be well-positioned to offer comprehensive solutions for both academic and pharmaceutical customers worldwide.”
The management of Cytena and its entity will remain the same after the acquisition is completed.
Source: Cytena
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
